HYCOR Biomedical news

While the first day of spring doesn’t arrive until March 20, by February tree pollens are already beginning to float through the mid-winter air. One of the most prevalent pollens at that time of year comes from the hazelnut tree but there is also substantial pollen present from cypress and alder trees.

In most parts of the continent, tree pollen season lasts from March until May, but in the south and east, due to warmer winter temper

Food Allergy Research and Education (FARE) has established that more than 32 million people in the US are victims of food allergy. Almost 8% of children with a food allergy are less than 5 years old and overall 4% of adults suffer from food allergies. Research conducted by NIH shows that more than 3.24% people in France have different types of food allergies. The study also shows that there is an increasing risk of food allergies in the upcoming decade (G Kanny, et. al., 2001). <

In 2018, HYCOR introduced the NOVEOS system with a revolutionary 4μL sample size that effectively eliminated common interferences (CCD and biotin) present in other mainstream allergy diagnostic systems. In 2021, HYCOR has now added to that groundbreaking step forward by introducing the NOVEOS Screen Inhalant mix that makes use molecular allergology to improve clinical strategies for patient care.

Using molecular techniques, more than one thousand molecules from

NOVEOS® DESIGNED WITH YOUR LAB IN MIND

Using extensive input from labs and clinicians around the world, the allergy-focused design brings unmatched competitive advantages. The NOVEOS system requires only 4-μL sample size per test which reduce quantity not sufficient errors, resampling and patient trauma. The advanced micro-particle technology limits interference from: Biotin, IgG / IgG4, and Solid-phase related cross-reactive carbohydrate de

This Christmas season, when families gather together and consume tasty holiday foods, it is essential to be aware of allergic reactions, which usually increase during this period.

Food allergies are estimated to affect 1% to 10% of adults and children in developed countries[1]. Notably, young children, especially to